X4 Pharmaceuticals Inc.

0.26
-0.01 (-4.09%)
At close: Mar 28, 2025, 3:59 PM
0.25
-1.99%
After-hours: Mar 28, 2025, 07:59 PM EDT
-4.09%
Bid 0.25
Market Cap 44.56M
Revenue (ttm) 3.62M
Net Income (ttm) -14.49M
EPS (ttm) -0.19
PE Ratio (ttm) -1.35
Forward PE -0.83
Analyst Buy
Ask 0.3
Volume 1,210,598
Avg. Volume (20D) 3,594,770
Open 0.26
Previous Close 0.27
Day's Range 0.26 - 0.28
52-Week Range 0.24 - 1.60
Beta 0.39

About XFOR

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and my...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2017
Employees 143
Stock Exchange NASDAQ
Ticker Symbol XFOR
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for XFOR stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 1069.13% from the latest price.

Stock Forecasts

Earnings Surprise

X4 Pharmaceuticals has released their quartely earnings on Mar 25, 2025:
  • Revenue of $1.43M exceeds estimates by $374K, with Infinity% YoY growth.
  • EPS of -0.2 misses estimates by -0.04, with -100.00% YoY decline.
  • Next Earnings Release

    X4 Pharmaceuticals Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    5 days ago
    -12.07%
    X4 Pharmaceuticals shares are trading lower follow... Unlock content with Pro Subscription
    1 month ago
    -10.83%
    X4 Pharmaceuticals shares are trading lower after the company announced a restructuring of its workforce and capital spending.